UCLA and Caltech integrated Cardiovascular Medicine for Bioengineers (iCMB)

摘要 该T32计划代表了培训生物物理学家和工程师遍历 心血管医学。工程与医学的融合正在改变临床和患者 通过用于传感和成像的灵活电子技术的进步，以及机器学习，提供护理 引入了新的创新，以应对日益流行的心脏代谢紊乱。伊利诺伊大学 加州大学洛杉矶分校(UCLA)和加州理工学院(Caltech)正在合作开发 加州大学洛杉矶分校/加州理工大学生物工程师综合心血管医学(ICMB)计划，将是 正式成为为期两年的结构化课程，重点是招聘代表性不足的员额 博士工程师或生物物理学家在学术界和工业界担任领导职务。该方法 在1)先进传感或2)成像与机器结合方面加强个性化培训 学习解决心脏代谢性疾病。ICMB计划将建立在两个成功基础上 加州理工学院和加州大学洛杉矶分校的联合培训计划：医学博士医学科学家培训计划(MSTP) 学生和独特的副专业培训和高级研究计划(STAR) 医生需要获得博士学位。与安进、强生等行业领先者的合作伙伴关系 美敦力和爱德华兹生命科学丰富了我们的实习、导师和领导力项目。 加州理工学院多样性中心和加州大学洛杉矶分校教师多样性和发展办公室都支持 科学、技术、工程和数学讲习班(STEM)，面向妇女和任职人数不足的人 少数族裔。为了实施ICMB计划，我们开发了一种新的指导和自我评估 结构包括24名经验丰富的导师、4名新任教员、22名临床教员(42%为女性)和10名 行业领先者。每名ICMB奖学金获得者将有共同导师关系：心脏代谢学的主要导师 一个是医学，另一个是使能技术或工业。在第一年，ICMB学者将发展 具备高级成像、传感器或计算的基础知识，并接受道德教育培训 生物医学研究和出版物。在第二年，ICMB奖学金获得者将有1)个选项参加 加州大学洛杉矶分校临床与翻译研究路径证书 美国食品和药物管理局监管科学研究所(CTSI)或法律与技术(BE188/299)；和/或2)参与 加州大学洛杉矶分校CTSI赞助的专业发展，为学术或行业职业生涯做准备。两者都有 加州理工学院和加州大学洛杉矶分校的院长承诺为每一位ICMB奖学金获得者提供匹配的资金。我们加州大学洛杉矶分校的副教务长 研究生教育还承诺为学员提供补充支持，以增加学员的多样性。 因此，加州理工大学/加州大学洛杉矶分校ICMB计划的互补和协同优势提供了一个新的 为解决全球流行的心脏代谢性疾病而准备的劳动力输注。

ABSTRACT This T32 program represents a new paradigm for training biophysical scientists and engineers to traverse cardiovascular medicine. The convergence of engineering with medicine is transforming clinical and patient care via advances in flexible electronics for sensing and imaging, coupled with machine learning, which has introduced new innovations to confront the rising endemic of cardiometabolic disorders. The University of California at Los Angeles (UCLA) and the California Institute of Technology (Caltech) are partnering to develop the UCLA/Caltech integrated Cardiovascular Medicine for Bioengineers (iCMB) Program, that will be formalized into a 2-year, structured curriculum with an emphasis on recruiting the under-represented post- doctoral engineers or biophysical scientists into leadership roles in academia and industry. The approach is to strengthen individualized training in 1) advanced sensing or 2) imaging coupled with machine learning to address 3) cardiometabolic disease. The iCMB program will be built upon two successful Caltech and UCLA joint training programs: the Medical Scientist Training Program (MSTP) for MD-PhD students and the unique Subspecialty Training and Advanced Research Program (STAR) for fellowship-level physicians to obtain a PhD. The partnerships with the industry leaders from Amgen, Johnson & Johnson, Medtronic, and Edwards Lifesciences have enriched our internship, mentorship, and leadership programs. Both the Caltech Diversity Center and UCLA Faculty Diversity & Development Office have supported workshops on Science Technology Engineering & Mathematics (STEM) for women and under-represented minorities. To implement this iCMB Program, we have developed a novel mentoring and self-evaluating structure in the inclusion of 24 seasoned mentors, 4 emerging faculty, 22 Clinical Faculty (42% female), and 10 industry leaders. Each iCMB scholar will have co-mentorships: a primary mentor from cardiometabolic medicine and a secondary from enabling technologies or industry. In Year 1, iCMB scholars will develop fundamental knowledge in advanced imaging, sensors, or computation and didactic training for ethics in biomedical research and publications. In Year 2, iCMB scholar will have an option 1) to participate in a certificate in Pathways in Clinical and Translational Research from the UCLA Clinical Translational Science Institute (CTSI) or Law and Technology for FDA regulatory science (BE188/299); and/or 2) to participate in UCLA CTSI-sponsored professional development in preparation for an academic or industry career. Both Caltech and UCLA Deans have committed matching funds for each iCMB scholar. Our Vice Provost for UCLA Graduate Education has also committed supplemental trainee support to enhance the diversity of trainees. Therefore, the complementary and synergistic strengths of the Caltech/UCLA iCMB Program provide a new infusion of workforce prepared to solve the worldwide endemic of cardiometabolic disease.